Arvaya Healthcare Completes 100% Acquisition of Sushodha Institute

Arvaya Healthcare has successfully acquired 1,84,374 equity shares, representing a 100% stake in Sushodha Institute of Gastroenterology Private Limited (SIGPL).

Effective November 1, 2026, SIGPL is now a wholly-owned subsidiary of Arvaya Healthcare Ltd.

Reader Takeaway: This acquisition strengthens Arvaya's gastroenterology vertical but integration efficiency and synergies will determine long-term margin impact.

What just happened

Arvaya Healthcare has concluded the acquisition of the entire equity share capital of SIGPL. The transaction follows the initial disclosure made to the stock exchange on October 24, 2026. The completion of this deal brings SIGPL formally under the Arvaya corporate umbrella, allowing for consolidated reporting starting from the current period.

Why this matters

This acquisition represents a strategic shift for Arvaya Healthcare to bolster its presence in specialized medical fields. By acquiring a dedicated gastroenterology institute, the company gains immediate operational capability in a niche segment. Investors should watch for how this addition influences the company's consolidated revenue streams and whether the integration delivers projected operational efficiencies.

What to track next

Moving forward, shareholders should look for details regarding the integration of SIGPL’s assets and personnel into Arvaya’s existing infrastructure. Key metrics to monitor in upcoming earnings reports include the revenue contribution from the gastroenterology vertical and any updates on capital expenditure required to scale these operations.